https://telogenis.com/delivery-matrix https://telogenis.com/delivery-matrix/images/supplement-core-10mg.jpg CAG CORE Supplement Facts Label — 10mg Cycloastragenol TELOGENIS CAG CORE Supplement Facts: Serving Size 1 Capsule, 30 Servings. Contains 10mg Cycloastragenol (≥99%), 535mg Liposomal Delivery Matrix, 135mg Solubility & Stability Complex (HPβCD, Syloid®), and 55mg Bioavailability Activation Complex (Fenugreek Gum, Ginger Extract 20% Gingerols, Bergamot Extract 5% Bergamottin, Sodium Caprate) https://telogenis.com/delivery-matrix/images/supplement-plus-20mg.jpg CAG PLUS Supplement Facts Label — 20mg Cycloastragenol TELOGENIS CAG PLUS Supplement Facts: Serving Size 2 Capsules, 30 Servings. Contains 20mg Cycloastragenol (≥99%), 1,070mg Liposomal Delivery Matrix, 270mg Solubility & Stability Complex (HPβCD, Syloid®), and 110mg Bioavailability Activation Complex https://telogenis.com/delivery-matrix/images/supplement-max-17mg.jpg CAG MAX Supplement Facts Label — 17mg Cycloastragenol TELOGENIS CAG MAX Supplement Facts: Serving Size 2 Capsules, 30 Servings. Contains 17mg Cycloastragenol, 1,150mg Liposomal Delivery Matrix, 210mg Solubility & Stability Complex (HPCD, Colloidal Silicon Dioxide, Ascorbyl Palmitate + Mixed Tocopherols), and 104mg Bioavailability Activation Complex (Ginger Extract 20%, Black Pepper Extract/Piperine, Naringin, Sodium Caprate) https://telogenis.com/delivery-matrix/images/absorption-core-10mg.jpg Enhanced Absorption Process Infographic — CAG CORE 10mg Four-stage delivery architecture for CAG CORE 10mg: (1) Solubility & Stability — HPβCD (135mg) + Syloid® encapsulates CAG molecules. (2) Liposomal & Lymphatic Transport — 535mg phospholipid bilayer. (3) Bioavailability Activation — CYP3A4 inhibition, P-gp modulation, tight junction support. (4) Systemic Absorption — lymphatic bypass of hepatic first-pass. Projected 65–80% bioavailability vs. <8.2% for other brands. Zhu et al. 2010 PMID:20877135. https://telogenis.com/delivery-matrix/images/absorption-plus-20mg.jpg Enhanced Absorption Process Infographic — CAG PLUS 20mg Four-stage delivery architecture for CAG PLUS 20mg with 1,070mg liposomal matrix, 270mg HPβCD complex, and 110mg bioactivation complex. Synergistic triple protection: inhibits CYP3A4, modulates P-gp, stabilizes CAG with HPβCD & liposomal delivery. Bypasses hepatic first-pass for greater systemic availability. https://telogenis.com/delivery-matrix/images/absorption-max-17mg.jpg Enhanced Absorption Process Infographic — CAG MAX 17mg Four-stage delivery architecture for CAG MAX 17mg with HPCD + antioxidant shield (210mg), 1,150mg liposomal matrix, and piperine/naringin bioactivation (104mg). Piperine documented 2–20× bioenhancement in published research. Naringin provides secondary CYP3A4 inhibition. LCT-driven lymphatic uptake bypasses hepatic first-pass.